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Background
Combination immunotherapy is quickly gaining attention
in the field of cancer treatment. IL-2, a cytokine which
activates T cells, and ipilimumab, a monoclonal antibody
that blocks CTLA-4, are both approved as monotherapy
for metastatic melanoma. To date, combination immu-
notherapy with IL-2 and anti-CTLA-4 has not been
adequately investigated. We hypothesized that that this
combination may work synergistically owing to its dis-
tinct but complementary mechanisms of T cell activation.
Methods
C57BL/6 mice (10 per group) were challenged with
B16-F10 melanoma (via intradermal injection with 120,000
cells) on day 0. Four groups were treated via intraperitoneal
injection: -Group 1 (combination): IL-2 (100,000 units in
100 µl) every 12 h on days 4-8 and anti-CTLA-4 (100 µg in
100 µl) on days 3, 6, and 9; -Group 2 (IL-2 only): IL-2
(100,000 units in 100 µl) every 12 h on days 4-8 and IgG
(100 µg in 100 µl) on days 3, 6, and 9; -Group 3 (anti-
CTLA-4 only): PBS (100 µl) every 12 h on days 4-8 and
anti-CTLA-4 (100 µg in 100µl) on days 3, 6, and 9; -Group
4 (placebo): PBS (100 µl) every 12 h on days 4-8 and IgG
(100 µg in 100 µl) on days 3, 6, and 9. Tumor area
(length*width) was measured every other day until death of
the animal or until tumors reached 100mm2, when animals
were sacrificed as per institutional protocols. Primary out-
comes included tumor size and overall survival.
Results
Tumor growth was significantly reduced with combina-
tion IL-2 and anti-CTLA-4. Specifically, on day 14, the
mean tumor area with combination IL-2 and anti-CTLA-
4 was 2mm2, while in the anti-CTLA-4 only, IL-2 only,
and placebo groups it was 14, 29, and 68 mm2, respec-
tively (P<0.01 for all comparisons, except IL-2 only ver-
sus anti-CTLA-4 only [not significant]). At day 30, the
overall survival with combination IL-2 and anti-CTLA-4
was 50%, while with IL-2 only and anti-CTLA-4 only it
was 10% and 20%, respectively (P<0.01 for all compari-
sons). All animals treated in the placebo group suc-
cumbed to their tumors by day 19. These findings were
confirmed in a second experiment with similar results.
Conclusions
Combination immunotherapy with IL-2 activation and
CTLA-4 blockade significantly decreases tumor growth
and increases overall survival when compared to IL-2 or
anti-CTLA-4 monotherapy or placebo. The role of CD8+
effector versus CD4+ regulatory T cells in the success of
this immunotherapy is ongoing and will be included in
our formal presentation. Ultimately, we aim to translate
this work into a combination immunotherapy clinical trial.
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